Each year in the United States, more than 500,000 neonates are born before 37 weeks of gestation. Women who have experienced a previous preterm birth are at high risk of recurrence. A weekly prenatal injection of 17a-hydroxyprogesterone caproate decreases the risk of recurrent preterm birth and is recommended from as early as 16 weeks of gestation in women carrying singleton pregnancies who have a history of spontaneous singleton preterm birth. A commonly used metric for public health program effectiveness is population coverage of an intervention. In the case of 17a-hydroxyprogesterone caproate, population coverage can be defined as the proportion of women who are eligible for 17a-hydroxyprogesterone caproate (ie, previous pregnancy complicated by spontaneous singleton preterm birth) who actually receive the intervention. To receive a full course of 17a-hydroxyprogesterone caproate, women must negotiate a complex series of steps that includes presenting early for prenatal care, being identified as eligible for 17a-hydroxyprogesterone caproate, being offered 17a-hydroxyprogesterone caproate, accepting 17a-hydroxyprogesterone caproate, and adhering to the weekly 17a-hydroxyprogesterone caproate dose schedule. We describe this series of steps as well potential solutions to increase 17a-hydroxyprogesterone caproate coverage. (Obstet Gynecol 2016;128:1397-402) DOI: 10.1097/AOG.0000000000001738 P reterm birth remains the leading cause of neonatal morbidity and mortality in the United States and accounts for a third of all infant deaths. 1 In 2015, the United States had the highest rate of preterm birth (9.5/100 live births) in the industrialized world, with more than 500,000 neonates born before 37 weeks of gestation each year. 2, 3 Although this rate has declined modestly in recent years, 4 most of the improvement can be attributed to a reduction in elective late preterm deliveries (35-37 weeks of gestation); rates of early preterm birth in the United States have hardly improved at all. 4 Ambitious national goals for reducing prematurity, including a decrease in the national preterm birth rate to 5.5% by 2030, have been advocated for by the March of Dimes. 5 Substantial decreases in national prematurity rates will only come with a well coordinated, multidisciplinary approach. Progress has been made in addressing some of the known modifiable risk factors for prematurity including declines in smoking during pregnancy, 6 increased access to early prenatal care, and further reduction in elective late preterm birth. 4 However, implementation of other evidence-based strategies to prevent preterm birth has been slower. Most prominent among these is widespread implementation of 17a-hydroxyprogesterone caproate for women with a singleton gestation and a history of spontaneous singleton preterm birth, a standard of care intervention that should be immediately implemented appropriately, broadly, and equitably.
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EVIDENCE FOR PROGESTOGENS FOR PREVENTION OF PRETERM BIRTH
In 2003, Meis and colleagues 7 published the results of a multicenter, placebo-controlled, randomized trial showing that administration of 17a-hydroxyprogesterone caproate to women with a previous spontaneous preterm birth reduced the risk of recurrent preterm delivery by 34%. Shortly after the publication of this study, the American College of Obstetricians and Gynecologists (the College) released a Practice Bulletin recommending that women with a singleton gestation and history of a previous spontaneous singleton preterm birth be offered 17a-hydroxyprogesterone caproate injections starting at 16-24 weeks of gestation. 8 Although there has been an abundance of publications on the individual patient efficacy of 17a-hydroxyprogesterone caproate, 9,10 little attention has been paid to system-level implementation of this U.S. Food and Drug Administration-approved intervention to reduce recurrent preterm birth.
MEASURING 17a-HYDROXYPROGESTERONE CAPROATE IMPLEMENTATION PROCESS INDICATORS
The available literature on monitoring 17a-hydroxyprogesterone caproate implementation is small but growing. Multiple retrospective reviews are now available in the literature that suggest the actual implementation of 17a-hydroxyprogesterone caproate may be falling short. In what appears to be an ideal clinical situation, where managed Medicaid in Missouri supported health education, weekly home nurse visits for 17a-hydroxyprogesterone caproate injections, and case managers to patients with a history of a spontaneous preterm birth, only 59% of 790 eligible patients initiated 17a-hydroxyprogesterone caproate within the recommended time frame, and 20% of these electively stopped the therapy before receiving a full course. 11 In a cross-sectional analysis of women followed up at a specialty high-risk prematurity clinic in Pennsylvania, Turitz and colleagues 12 found that 75% of women had documentation of receipt of 17a-hydroxyprogesterone caproate. Our group conducted a retrospective study among women delivering at two tertiary care institutions in North Carolina and found that only 47% of women with a previous spontaneous preterm birth and a current singleton gestation had documentation of receipt of at least one dose of 17a-hydroxyprogesterone caproate. 13 On a population basis, reports of the simplest process-level indicators for administration of 17a-hydroxyprogesterone caproate, such as number of patients offered or accepting 17a-hydroxyprogesterone caproate, are limited. One report from Louisiana describes 7.4% of the Medicaid population having received 17a-hydroxyprogesterone caproate in 2013, although it is not clear from the publication how the data were obtained. 14 Other states, such as Ohio, 15 report ongoing measurement of 17a-hydroxyprogesterone caproate, but the literature remains very limited in terms of published accounts. Numerous medical societies in the United States, including the Society for Maternal-Fetal Medicine, the American College of Nurse-Midwives, and the College, have endorsed the use of 17a-hydroxyprogesterone caproate. 8, 10, 16 Only the College has proposed a metric for the monitoring of 17a-hydroxyprogesterone caproate: the number of eligible women offered the medication. 8 Although this metric is a starting point, it falls short of providing sufficient information to understand why 17a-hydroxyprogesterone caproate is not being used and, by extension, how to improve its use.
A commonly used surrogate marker for public health program effectiveness is population coverage of an intervention. By using coverage as a surrogate for effectiveness, we assume that the efficacy from clinical trials will redound to those women who fully access the intervention. In the case of 17a-hydroxyprogesterone caproate, we define population coverage as the proportion of pregnant women with a previous spontaneous preterm birth of a singleton who receive a full course of the intervention.
For the known benefit of 17a-hydroxyprogesterone caproate to accrue to a given mother-neonate pair, the pregnant woman must navigate a critical path of events that begins with attending prenatal care and being identified as eligible for the intervention and then proceeds through being offered, accepting, and actually receiving the 17a-hydroxyprogesterone caproate injections. We describe this critical path as the 17a-hydroxyprogesterone caproate Cascade. We note that attrition can occur at any point along the path, resulting in failed coverage. Table 1 outlays potential barriers to 17a-hydroxyprogesterone caproate initiation and continuation along the 17a-hydroxyprogesterone caproate Cascade. For each step in the cascade, we describe barriers and propose solutions.
Attend Antenatal Care
For a woman to be eligible to receive the full course of 17a-hydroxyprogesterone caproate and access its maximal benefit, she must attend antenatal care early enough to begin prophylaxis before 20 weeks of gestation. Women without prepregnancy health insurance may face delays in obtaining an initial obstetric care appointment and in receiving preapproval for the 17a-hydroxyprogesterone caproate prescription. In 2009, before implementation of the Affordable Care Act, 30% of women in one study reported either no insurance or change of insurance around the time of pregnancy. 17 Racial disparities continue to exist around access to care; African American women are Unauthorized reproduction of this article is prohibited.
significantly less likely to initiate care in the first trimester than are Caucasian or Latina women. 18, 19 Solutions to addressing early access to medical insurance as well as ease with obtaining appointments include promoting early diagnosis of pregnancy with urine pregnancy tests at the clinic level and initiating the process of registering women without medical insurance as soon as pregnancy is diagnosed. In some states, presumptive Medicaid activation at pregnancy diagnosis allows women an immediate payment mechanism for prenatal care while awaiting formal insurance. Other solutions include community-and clinic-based education to encourage women to visit public health clinics early to diagnose pregnancy. Additionally, we must not miss the opportunity to educate patients around the time of their spontaneous preterm birth about what to expect in subsequent pregnancies, including availability of 17a-hydroxyprogesterone caproate. These messages can be reinforced during the postpartum and interconception periods and include the need for early presentation for prenatal care.
Recognizing Women as Eligible for 17a-Hydroxyprogesterone Caproate
Once a woman with a previous preterm birth is engaged in prenatal care, providers must recognize her as eligible for 17a-hydroxyprogesterone caproate based on her obstetric history. As straightforward as this may seem, it can be difficult if medical records are not available from her previous delivery or deliveries. Women may not know the gestational age at which they previously delivered or the indication for their delivery, making it hard for clinicians to determine eligibility. The College and the Society for Maternal-Fetal Medicine guidelines state that to be eligible for 17a-hydroxyprogesterone caproate a woman must have "a current singleton pregnancy and a prior spontaneous singleton preterm birth." 8 However, these guidelines are silent on whether Unauthorized reproduction of this article is prohibited.
17a-hydroxyprogesterone caproate is indicated when the previous preterm birth occurred very early (eg, before 20 weeks of gestation), when other circumstances prevailed (eg, placental abruption), or when clarity is lacking as to whether the previous preterm birth was spontaneous or not. Some providers may be uncomfortable determining whether the woman is eligible from her previous birth history and choose to refer women to larger medical centers for consultation and to receive weekly 17a-hydroxyprogesterone caproate. We advocate for provision of care locally whenever possible. Open communication between community providers, nurses, physicians, and tertiary care centers can empower clinic-level providers to confidently identify women who are eligible for 17a-hydroxyprogesterone caproate, avoiding unnecessary referral. Integrated electronic medical records between clinics and hospitals may also help with improved information flow. Supporting providers at local health clinics with clinical questions on a regular basis by telephone, telemedicine, or biweekly or monthly clinic visits is another way to help local providers feel confident with current recommendations and understand how to identify women who are eligible for 17a-hydroxyprogesterone caproate.
Offering the Intervention
Patients may not be offered 17a-hydroxyprogesterone caproate because their providers are unsure of eligibility requirements or unconvinced of its efficacy. 20 Some data, including our own, suggest that women whose obstetric history includes a late preterm birth are less likely to be offered 17a-hydroxyprogesterone caproate than women with an early preterm birth. 13 Ensuring that providers are up to date on the most recent guidelines may help coverage of the intervention. Supporting providers so they are able to more easily prescribe the drug is another way to improve utilization. Currently, there is considerable variation among insurance providers around the requirements for prescribing 17a-hydroxyprogesterone caproate. Differences exist as to which formulation of 17a-hydroxyprogesterone caproate a given insurance provider will cover (ie, proprietary or compounded drug), who can actually write the prescription, at what gestational age the drug can be started, and whether 17a-hydroxyprogesterone caproate is considered a medical benefit or a pharmacy benefit. Although there are not many published data on the prescribing process, in our experience, the process of ordering compounded 17a-hydroxyprogesterone caproate can be more streamlined than ordering the proprietary formulation. With shrinking numbers of compounding pharmacies manufacturing 17a-hydroxyprogesterone caproate, prescribing providers must order the proprietary formulation. Most insurers require preauthorization, especially for the proprietary brand of 17a-hydroxyprogesterone caproate, and from personal communications with providers in different states, the process of obtaining preauthorization is laborious and may influence a provider's willingness or ability to offer the drug.
Acceptance and Adherence
Finally, once prescribed, a woman must accept the intervention and adhere to its weekly injection schedule, which can be as many as twenty doses. Women may not accept the medication because of skepticism of the medication's effectiveness or aversion to injections, There are many logistical barriers that may affect the ability of a woman who desires 17a-hydroxyprogesterone caproate to actually receive it. Preauthorization, which may take a long time, can be a major barrier to women starting 17a-hydroxyprogesterone caproate at the recommended gestational age. Copayments for the medication may also inhibit access to this drug. Streamlining the ordering process would likely help this process. Many reasons exist as to why patients are nonadherent to 17a-hydroxyprogesterone caproate, including child care and other structural barriers, such as lack of transportation that make a weekly trip to the clinic difficult. In a recent retrospective chart review, African American women were more likely to miss one or more doses of 17a-hydroxyprogesterone caproate. 21 Home administration may be one solution to these barriers and so may be transportation reimbursements for women to get to the clinic. The multidose vial has also been a barrier because women may have received a dose at a referral clinic but are then unable to receive additional doses from the vial at her local clinic. With the new singular vial dosing it will be easier for women to access 17a-hydroxyprogesterone caproate at their regular prenatal clinics and at referral clinics if there is comanagement occurring.
DISCUSSION
Preterm birth remains among the most important unsolved problems of modern obstetrics. Although 17a-hydroxyprogesterone caproate is not a panacea, it is among the only known effective interventions that are currently available to us. As such, it seems foolish not to maximize its use. The 17a-hydroxyprogesterone caproate cascade described in this article is a simple rubric that can be used to systematically measure Unauthorized reproduction of this article is prohibited.
the performance of a system to deliver the drug. We have found that the measurement is amenable to an iterative quality-improvement approach, where periodic performance reports can be reviewed and systemic improvements made. At the clinic level, this might involve a staff discussion around the barriers to patient adherence. On a more macro level, such as state Medicaid decision makers, the measurement might help identify facilities or practices that need additional training or resources. Until a commitment is made to actually measure 17a-hydroxyprogesterone caproate coverage, understand the reasons for failed coverage, and act upon our findings, we will likely continue to fall short in our delivery of this known effective intervention.
